Human CD30-Specific Antibodies with Localized Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antigen-binding affinity reagents lack specificity and efficacy in targeting human CD30, particularly in distinguishing between human and mouse CD30, and do not effectively inhibit CD30 signaling.
Innovation Solution
Development of novel binding proteins, including monoclonal, humanized, and chimeric antibodies, with specific heavy and light chain variable regions that target human CD30 with high affinity, preventing cross-reactivity with mouse CD30 and incorporating detection or purification moieties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antigen-binding affinity reagents are used, then general CD30 binding is achieved, but specificity for human CD30 over mouse CD30 is lost
Solution Approach 1:
The antibody variable regions are engineered with specific amino acid sequences that create local binding characteristics selective for human CD30 epitopes. The CDR regions contain human-specific sequence motifs that locally recognize human CD30 structural features while excluding mouse CD30, achieving species-specific binding through localized sequence optimization.
Solution Approach 2:
The binding parameters of the antibody are optimized through systematic variation of CDR amino acid sequences. By changing specific residues in the variable regions, the antibody's affinity and specificity parameters are tuned to preferentially bind human CD30 with KD ≤ 5.1 nM while reducing cross-reactivity with mouse CD30.
2Reliability
If high affinity binding to human CD30 is achieved, then therapeutic efficacy is improved, but risk of off-target effects increases
Solution Approach 1:
The antibody's binding interface is engineered with localized specificity features that recognize unique human CD30 epitopes not present in mouse or other species. This localized human-specific recognition ensures high therapeutic efficacy against human CD30-expressing cells while minimizing off-target binding to homologous proteins in other species.
Solution Approach 2:
The patent converts the potential harm of cross-reactivity into a benefit by deliberately designing the antibody to exploit subtle differences in human versus mouse CD30 sequences. The antibody is engineered to bind human-specific structural features, turning what could be non-specific cross-reactivity into highly specific human CD30 targeting.
3Ease of manufacture
If conventional antibody structures are used, then ease of production is maintained, but functional versatility is limited
Solution Approach 1:
The antibody is designed with a versatile platform architecture that maintains conventional IgG structural features for ease of production while incorporating modular functional domains. The Fc region can be engineered for different effector functions, and the variable regions can be grafted onto different constant regions, enabling a single binding specificity to serve multiple therapeutic and diagnostic applications.
Solution Approach 2:
The antibody structure is segmented into modular functional regions: the variable regions provide human-specific CD30 binding, while the constant regions provide effector functions. This segmentation allows independent optimization of binding specificity and effector activities, enabling the same binding protein to be adapted for different applications such as ADCs, bispecifics, or diagnostic reagents.
Data Source
AI summary
Embodiments of the present disclosure relate to antigen-binding affinity reagents for an analyte-of-interest. In particular, the present disclosure provides novel binding proteins (antibodies), including derivatives and fragments thereof, that target human CD30.